Aprotinin is a serine protease inhibitor used in high-risk patients undergoing cardiopulmonary bypass for coronary artery bypass graft surgery to lower the risk of perioperative blood loss and the requirement for blood transfusions. Aprotinin (Trasylol, formerly Bayer and now Nordic Group pharmaceuticals) is a tiny protein bovine pancreatic trypsin inhibitor (BPTI), also known as basic trypsin inhibitor of bovine pancreas, which is Trypsin and related proteolytic enzymes are inhibited by an antifibrinolytic compound. Aprotinin was marketed as Trasylol, a medicine that was injected to minimize bleeding during complicated surgeries such as heart and liver operations. Its main action is to slow down fibrinolysis, the process that causes blood clots to dissolve. Its use was intended to reduce the need for blood transfusions during operation, as well as end-organ damage caused by hypotension (low blood pressure) caused by significant blood loss. After investigations revealed that using the medicine raised the risk of complications or death, the drug was temporarily removed worldwide in 2007. This was verified by follow-up studies. Trasylol sales were halted in May 2008, except for very limited research use. The European Medicines Agency's (EMA) scientific committee reversed its previous position on aprotinin in February 2012, recommending that the suspension be lifted. In 2012, Nordic became an aprotinin distributor.

Aprotinin, commonly known as BPTI (Trasylol, Bayer) or bovine pancreatic trypsin inhibitor, is a medication used to prevent bleeding during cardiopulmonary bypass (CPB). Aprotinin slows fibrinolysis, the process that causes blood clots to dissolve.

An online search for the wholesale price for sale of Aprotinin for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Aprotinin distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Aprotinin suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Aprotinin. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Aprotinin is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers' Aprotinin suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Aprotinin Manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.